Revolutionizing cancer trial search for patients with AI.
Testing with CLL patients.
Clinical trials open doors to breakthrough treatments, but too many patients still struggle to find trials that fit their diagnosis, stage, and personal needs.
Before and after Almara.
CLL patients used Almara during a structured testing program. The shift in time-to-relevance and outcome quality was immediate.
Status quo
- Most patients had searched for trials before, often with no success
- 67% were unsatisfied or found no actionable results
- Average search took ~40 minutes and felt confusing
- Information felt dense and hard to interpret
With Almara
- 86.5% received relevant, actionable matches
- 84.7% would use Almara again
- Average search took ~10 minutes
- Clear, shareable results for care-team conversations
86.5% of results were potentially actionable.
Participants reported the trial results were actionable and made them feel better prepared to talk with their care teams.
“Four of the six studies were flagged appropriately as highly relevant. I already knew of two. Impressive.”
Three motivations stood out.
Discover trials for current or future treatment
Finding relevant options for immediate or potential future needs.
Understand options across the disease course
Exploring possibilities for watch-and-wait or relapsed/refractory cases.
Make trial search easier for the next patient
Sharing input to improve the experience for others facing similar challenges.
79.1% described Almara as simple to use.
The vast majority of CLL patients found Almara simple, proving that AI-powered matching can feel human, clear, and empowering.
“It is very well laid out and easy to navigate.”
“Very straightforward. Very clear qualifying questions.”
“I would recommend this site for anybody looking for more information on clinical trials.”
Almara is built for every cancer.
The CLL study validated the approach. We're partnering with cancer centers and advocacy groups to bring the same experience to patients across every diagnosis.